Skip to main content

SR One — Portfolio, Page 2

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

65
Companies
$4.4B
Total invested
$105.1M
Avg. check
11
Industries
Health Care 20Biotechnology 19Therapeutics 12Medical 12Life Science 8Biopharma 8+5 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 2548 of 65
Addition Therapeutics
December 2025

Addition Therapeutics develops RNA-only therapeutics using PRINT technology for genetic medicine.

Biotechnology · South San Francisco$100.0M Series A
HotSpot Therapeutics
November 2021

HotSpot Therapeutics is a developer of a therapy platform designed to discover medicines and provide proper treatment.

Biopharma · Boston$100.0M Series C
Arcellx
November 2023

Arcellx develops engineered cell-based immunotherapies for the treatment of cancer and other serious diseases.

Biopharma · Redwood City$200.0M Post-IPO Equity
CORXEL Pharmaceuticals
January 2026

CORXEL Pharmaceuticals is a biotechnology company that develops science and medicines for underserved patients.

Biotechnology · Shanghai$287.0M Series D
AirNexis Therapeutics
January 2026

AirNexis Therapeutics develops clinical-stage therapies for chronic obstructive pulmonary disease and other pulmonary conditions.

Biotechnology · Palo Alto$200.0M Series A
Poplar Therapeutics
January 2026

Poplar Therapeutics anti-IgE therapy treats atopic diseases such as food allergy, allergic asthma, and atopic dermatitis.

Health Care · Cambridge$50.0M Series A
Alumis
January 2026

Alumis is a precision medicine company focused on the discovery, development and treatment of autoimmune disorders.

Biotechnology · San Francisco$345.1M Post Ipo Equity
VeraDermics
October 2025

VeraDermics is a dermatology company that creates novel drug delivery mechanisms for a pain-free cure for skin conditions.

Health Care · New Haven$150.0M Series C
MISSION Therapeutics
October 2025

MISSION Therapeutics develops therapies that enhance the removal of dysfunctional mitochondria to combat serious diseases.

Biotechnology · Cambridge$13.3M Series Unknown
Zenas BioPharma
October 2025

Zenas BioPharma is a biopharmaceutical company that focuses on developing immune-based therapies for patients.

Biopharma · Waltham$120.0M Post Ipo Equity
Crystalys Therapeutics
September 2025

Crystalys Therapeutics is a clinical-stage biopharmaceutical company transforming the treatment of gout.

Biopharma · San Diego$205.0M Series A
ARS Pharmaceuticals
September 2025

ARS Pharmaceuticals is a stealth pharmaceutical company that specializes in developing anti allergy drugs.

Biopharma · San Diego$100.0M Post Ipo Debt
Odyssey Therapeutics
September 2025

Odyssey Therapeutics creates precision immunomodulators and oncology medicines for patients with cancer and inflammatory diseases.

Biotechnology · Cambridge$213.0M Series D
Avenzo Therapeutics
September 2025

Avenzo Therapeutics specializes in the development of oncology therapies for cancer treatment.

Biotechnology · San Diego$60.0M Series B
Draig Therapeutics
June 2025

Draig Therapeutics is a clinical-stage biopharmaceutical startup.

Biopharma · Cardiff$140.0M Series A
ORIC Pharmaceuticals
May 2025

ORIC Pharmaceuticals is a biopharmaceutical company that develops treatments that target the causes of therapeutic resistance.

Biopharma · South San Francisco$125.0M Post Ipo Equity
Fore Biotherapeutics
May 2025

Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics.

Biotechnology · Philadelphia$40.2M Series D
ADARx Pharmaceuticals
February 2025

ADARx Pharmaceuticals is a genetic medicine company focusing on the base editing of mRNA transcripts.

Biotechnology · San DiegoSeries Unknown
Windward Bio
January 2025

Windward Bio develops monoclonal antibodies for advanced immunological diseases.

Biotechnology · Basel$200.0M Series A
Akamis Bio
December 2024

Akamis Bio is a clinical-stage oncology company.

Biotechnology · Abingdon$60.0M Series A
Antag Therapeutics
December 2024

Antag Therapeutics provides therapeutic peptides for the treatment of dietary-related metabolic diseases.

Biotechnology · Copenhagen$84.1M Series A
Dren Bio
July 2024

Dren Bio focuses on protein engineering technologies for depletion of cells, protein aggregates, and other disease-causing agents.

Biotechnology · Foster City$25.0M Corporate Round
Renalys Pharma
July 2024

Renalys Pharma is a clinical-stage biopharmaceutical company developing therapeutics for renal disease in Asian patients.

Biopharma · Tokyo$38.5M Series A
Effector Therapeutics
January 2024

Effector Therapeutics is an early-stage company focused on the discovery and development of small molecule cancer therapeutics.

Biotechnology · San Diego$15.0M Post Ipo Equity

Where SR One invests

Health Care20
Biotechnology19
Therapeutics12
Medical12
Life Science8
Biopharma8

About SR One's portfolio

How many companies has SR One invested in?

SR One has invested in 65 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does SR One invest in?

SR One's top investment sectors include Health Care, Biotechnology, Therapeutics, Medical, Life Science. The firm invests across 11 different industry categories.

What is SR One's largest investment?

Among tracked funding rounds, Alumis received $345.1M in a Post Ipo Equity round. SR One's total known invested capital is $4.4B.

What is the average investment size for SR One?

SR One's average investment size is $105.1M across its portfolio of 65 companies.

What are SR One's most recent investments?

Recent SR One portfolio additions include Addition Therapeutics, HotSpot Therapeutics, Arcellx, CORXEL Pharmaceuticals, AirNexis Therapeutics. These companies were founded in 2020 or later.

Reach the founders behind these 65 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →